In vitro and in vivo evaluation of a posaconazole‐sulfobutyl ether‐β‐cyclodextrin inclusion complex

Published on Dec 1, 2018in Biomedical Chromatography1.728
· DOI :10.1002/BMC.4364
Miao Wang9
Estimated H-index: 9
(SPU: Shenyang Pharmaceutical University),
Juan Jiang2
Estimated H-index: 2
(SPU: Shenyang Pharmaceutical University)
+ 4 AuthorsChunjie Zhao6
Estimated H-index: 6
(SPU: Shenyang Pharmaceutical University)
: Posaconazole (PCZ) is a triazole antifungal agent with an extended spectrum of antifungal activity. It is approved for the prophylaxis of invasive fungal infections in patients with neutropenia or in hematopoietic stem cell transplant recipients undergoing high-dose immunosuppressive therapy for graft-vs-host disease, and for the treatment of fungal infections. However, its pharmacological effects are severely limited owing to its poor solubility and low bioavailability. In order to solve these problems, a sulfobutyl ether-β-cyclodextrin compound was used to prepare an intramuscular injection to improve the bioavailability of posaconazole. The extracorporeal dissolution rate of posaconazole was markedly improved by this inclusion complex with >90% being released within 5 min, and the in vivo pharmacokinetics were studied using a HPLC/MS/MS method for quantifying posaconazole and the posaconazole-sulfobutyl ether-β-cyclodextrin inclusion complex in rat blood. Posaconazole and an internal standard, itraconazole, were extracted by protein precipitation using acetonitrile. The concentration range of posaconazole was 0.05-4.0 μg/mL with good linearity (r = 0.9980), the peak concentrations of pure posaconazole and the inclusion complex were 0.565 ± 0.102 μg/mL and 1.12 ± 0.091 μg/mL, the values for AUC0-t were 12.2 ± 2.5 and 19.9 ± 2.5 μg h/mL, and the values for AUC0-∞ were 16.4 ± 3.2 and 25.0 ± 3.5 μg h/mL, respectively. The main pharmacokinetics parameters showed significant differences (P < 0.01). Compared with pure posaconazole, the posaconazole-sulfobutyl ether-β-cyclodextrin inclusion complex markedly improved the bioavailability of posaconazole.
📖 Papers frequently viewed together
5 Authors (Carsten Müller, ..., M. Theisohn)
32 Citations
52 Citations
#1L. Thakuria (Harefield Hospital)H-Index: 1
#2K. Packwood (Harefield Hospital)H-Index: 3
Last. Anna Reed (Harefield Hospital)H-Index: 15
view all 20 authors...
Abstract Invasive fungal infections cause significant morbidity and mortality after lung transplantation. Fungal prophylaxis following lung transplantation is not standardised, with transplant centres utilising a variety of regimens. Posaconazole is a broad-spectrum antifungal triazole that requires further investigation within the setting of lung transplantation. This prospective, single-centre, observational study explored the pharmacokinetics of posaconazole oral suspension (POS) in the early...
11 CitationsSource
#1Jason N. Moore (Thomas Jefferson University)H-Index: 5
#2Jason R. Healy (Thomas Jefferson University)H-Index: 3
Last. Walter K. Kraft (Thomas Jefferson University)H-Index: 27
view all 3 authors...
Posaconazole, a broad-spectrum triazole antifungal agent, is approved for the prevention of invasive aspergillosis and candidiasis in addition to the treatment of oropharyngeal candidiasis. There is evidence of efficacy in the treatment and prevention of rarer, more difficult-to-treat fungal infections. Posaconazole oral suspension solution has shown limitations with respect to fasting state absorption, elevated gastrointestinal pH and increased motility. The newly approved delayed-release oral ...
25 CitationsSource
#1Anthony J. Guarascio (Duquesne University)H-Index: 7
#2Douglas Slain (WVU: West Virginia University)H-Index: 17
The triazole antifungal posaconazole was first approved as an oral suspension formulation. Despite pharmacokinetic target attainment and clinical efficacy in premarketing trials, postmarketing analyses indicated unpredictable bioavailability resulting in subtherapeutic concentrations and reports of breakthrough fungal infections. The newly approved posaconazole delayed-release tablet and intravenous formulations display more consistent bioavailability in the presence of concomitant disease state...
36 CitationsSource
#1Hua Liu ('SMMU': Second Military Medical University)H-Index: 3
#2Guang Yang ('SMMU': Second Military Medical University)H-Index: 6
Last. Guorong Fan ('SMMU': Second Military Medical University)H-Index: 27
view all 7 authors...
β-Caryophyllene (BCP), a natural sesquiterpene existing in the essential oil of many plants, has exhibited a wide range of biological activities. However, its volatility and poor water-solubility limit its application in pharmaceutical field. β-Cyclodextrin (β-CD) has intrinsic ability to form specific inclusion complexes with different drugs to enhance their stability, solubility and bioavailability. The aim of this study is to investigate and compare the oral bioavailability and the pharmacoki...
64 CitationsSource
#1Sabrina Cencig (ULB: Université libre de Bruxelles)H-Index: 4
#2Nicolas Coltel (ULB: Université libre de Bruxelles)H-Index: 3
Last. Yves Carlier (ULB: Université libre de Bruxelles)H-Index: 49
view all 4 authors...
Abstract The present work aimed to investigate the curative effect of benznidazole (BZL) in combination with other patented drugs [nifurtimox (NFX), posaconazole (POS) or AmBisome ® (AMB)] in mice acutely or chronically infected with either a BZL-susceptible (Tulahuen) or a BZL-partially-resistant (Y) strain of Trypanosoma cruzi . To appreciate the eventual advantage of such combinations, infected mice were treated for short durations (non-curative) of each individual treatment. Cure rates were ...
60 CitationsSource
#1Gopal Krishna (MSD: Merck & Co.)H-Index: 30
#2Lei Ma (MSD: Merck & Co.)H-Index: 15
Last. Edward O'Mara (MSD: Merck & Co.)H-Index: 9
view all 5 authors...
Objectives Posaconazole is an extended-spectrum triazole with proven efficacy as antifungal treatment and prophylaxis. The marketed oral suspension should be taken with food to maximize systemic absorption. A new solid oral tablet has been developed with improved bioavailability that can be administered without regard to food. The aim of this study was to evaluate rising single- and multiple-dose pharmacokinetics, safety and tolerability of the new tablet.
116 CitationsSource
#1C.P.W.G.M. Verweij-van Wissen (Radboud University Nijmegen Medical Centre)H-Index: 6
#2David M. Burger (Radboud University Nijmegen Medical Centre)H-Index: 70
Last. Roger J. M. Brüggemann (Radboud University Nijmegen Medical Centre)H-Index: 39
view all 5 authors...
A reversed phase ultra-performance liquid chromatography method was developed for the simultaneous quantitative determination of the systemically administered azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in plasma. The method involved a simple liquid-liquid extraction followed by ultra-performance liquid chromatography with an Acquity UPLC BEH Phenyl column and ultraviolet detection set at a wavelength of 260 nm. The assay was validated o...
37 CitationsSource
#1Zimei Wu (University of Auckland)H-Index: 26
#2Ian G. Tucker (University of Otago)H-Index: 29
Last. Natalie J. Medlicott (University of Otago)H-Index: 19
view all 6 authors...
Abstract Post-injection precipitation may cause poor and erratic drug absorption and tissue irritation at the injection site. Tissue tolerance and pharmacokinetics of a low pH ricobendazole (RBZ) injectable containing 20% hydroxypropyl-β-cyclodextrin (HP-β-CD) were simultaneously investigated after subcutaneous injection in sheep compared to a reference formulation without HP-β-CD. Each animal received a RBZ containing formulation on one side of the back and the respective vehicle on the contral...
11 CitationsSource
#1Wei Yang (University of Texas at Austin)H-Index: 10
#2Keat Theng Chow (University of Texas at Austin)H-Index: 8
Last. Robert O. Williams (University of Texas at Austin)H-Index: 61
view all 6 authors...
Abstract This study aims to make a 2-hydroxypropyl-β-cyclodextrin (HPβCD) solubilized itraconazole (ITZ) solution (i.e., HPβCD-ITZ) suitable for pulmonary delivery by nebulization, and compare pharmacokinetics of inhaled nebulized aerosols of HPβCD-ITZ versus a colloidal dispersion of ITZ nanoparticulate formulation (i.e., URF-ITZ). Solid state characterizations of lyophilized HPβCD-ITZ by differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR) and X-ray photoelec...
53 CitationsSource
#1Gopal Krishna (Schering-Plough)H-Index: 30
#2Lei Ma (Schering-Plough)H-Index: 15
Last. Steven Komjathy (PRA Health Sciences)H-Index: 3
view all 8 authors...
The aim of this single-center, phase 1, randomized, 5 by 5 crossover, open-label study was to determine the effects of varying amounts of a nutritional supplement (Boost Plus) on the pharmacokinetics of posaconazole in 30 healthy volunteers. After an overnight fast, subjects were administered a single dose of 400 mg posaconazole oral suspension alone or following Boost Plus (8 fluid ounces [oz] [240 ml], 4 oz [120 ml], 2 oz [60 ml], or 1 oz [30 ml]). Subjects were randomized to receive all five ...
69 CitationsSource
Cited By2
#1Qurrat-Ul-Ain Khan (UVAS: University of Veterinary and Animal Sciences)
#2Muhammad Irfan Siddique (UVAS: University of Veterinary and Animal Sciences)H-Index: 5
Last. Muhammad Zaman (University of Central Punjab)H-Index: 12
view all 6 authors...
Patients suffering from dysphagia have trouble in swallowing conventional oral dosage forms and there is also risk of choking, which may cause patient noncompliance. This study aimed to develop an ...
#2Fernanda Ílary Costa Duarte (UFRN: Federal University of Rio Grande do Norte)H-Index: 2
Last. Ádley Antonini Neves de Lima (UFRN: Federal University of Rio Grande do Norte)H-Index: 9
view all 7 authors...
This review aims to provide a critical review of the biological performance of natural and synthetic substances complexed with cyclodextrins, highlighting: (i) inclusion complexes with cyclodextrins and their biological studies in vitro and in vivo; (ii) Evaluation and comparison of the bioactive efficacy of complexed and non-complexed substances; (iii) Chemical and biological performance tests of inclusion complexes, aimed at the development of new pharmaceutical products. Based on the evidence...
60 CitationsSource